ICON and ICHOM are creating the world's first global healthcare outcomes benchmarking program DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and ...
The U.S. FDA has selected Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials. With the help of the Biomarkers Consortium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results